Treating Both Cholesterol and Inflammation

Numerous studies have shown that cholesterol-lowering treatment with statin drugs reduces the risk of a future heart attack or death. One of these studies, the PROVE IT-TIMI 22 trial, has recently provided much new information on how statin therapy lowers that risk...(more)

An Overview for Beginners on High-Sensitivity C-Reactive Protein (hs-CRP)

In this presentation Dr. Koenig addresses some commonly encountered questions about C-reactive protein (CRP) and the significance of high sensitivity CRP (hs-CRP) testing in clinical practice. CRP is a molecule produced by the liver in response to inflammation,...(more)

Inflammation and Atherosclerosis

Heart attacks are a major cause of death around the world, and much research has focused lately on the underlying causes of heart attacks, and how this knowledge can be used in medical practice to help prevent the occurrence of such events. “Atherosclerosis” or...(more)

Blood Pressure, Blood Pressure Therapy, and C-Reactive Protein (hsCRP): A Patient Based Update

Inflammation is a process by which the body heals itself, however, chronic inflammation is implicated in some disease states, such as rheumatoid arthritis. Recently, atherosclerosis has also come to be understood as an inflammatory disease (1). C-reactive...(more)

Do patients on statin therapy need hsCRP measured? Update January 2005

High sensitivity C-reactive protein (hsCRP) is a measuement of inflammation, and numerous large studies have shown that high hsCRP levels increase the risk of having a future heart attack or stroke. As a result of these data, doctors can now use hsCRP measurements...(more)

An Introduction to High-Sensitivity C-Reactive Protein (hs-CRP) for Patients: Can We Better Predict Heart Attack and Stroke?

In this presentation Dr. Ridker addresses the question of whether high-sensitivity C-reactive protein (hs-CRP) can be used to better predict the risk of heart attack and stroke. High blood pressure, smoking, diabetes and high cholesterol are classical risk...(more)